Herpes simplex virus (HSV) causes significant health problems in the USA (Fleming et al., 1997; Liesegang, 2001 ). Each year, there are an estimated 500 000 new cases of symptomatic HSV-2 infection (Xu et al., 2002) . HSV-2 causes primarily genital infections, but is also capable of causing necrotizing stromal keratitis, encephalitis, meningitis and neonatal ophthalmic and neurological complications in infants surviving infection (Stanberry et al., 1997; Sucato et al., 1998) . HSV skin infections are rarely fatal, but the presence of herpetic lesions on a mother places the baby at risk for HSV entry into the eye during birth. This may lead to blindness in the child, especially if the mother acquires HSV-2 during the third trimester (Brown, 2004) . Immunohistochemistry studies have indicated the concurrent expression of specific HSV-2 antigens in corneal epithelial cells, in keratocytes of the corneal stroma and in the endothelial cells (Rummelt et al., 1995) . It has also been shown in animal models that HSV-2 grows to higher titres and is more efficient at causing necrotizing stromal keratitis and encephalitis than HSV-1 (Stanberry et al., 1997) . Recently, a case of stromal keratitis and anterior uveitis due to HSV-2 infection was reported in a young child (Inoda et al., 2001) . HSV-2 is also more neurovirulent than HSV-1 in neonates who survive an initial infection, and is more likely to lead to meningitis in patients with primary genital infections (Smith et al., 2000) . As HSV establishes a latent infection in the sensory ganglia, those infected are at continual risk for the development of herpetic stromal keratitis (HSK), which may lead to decreased vision or blindness due to corneal scarring, thinning and vascularization (Colin, 2002) .
Despite the severity of HSV-2 corneal infections, it is not known which cellular receptor(s) is crucial for HSV-2 entry into the cells of the corneal stroma. It is known in general that HSV entry into host cells is a multi-step process that begins with the initial binding of viral envelope glycoproteins to host-cell surface receptors. It has been documented that glycoproteins B and C (gB and gC) mediate the initial attachment or binding of the virions to cell-surface glycosaminoglycans, the most prominent of which is heparan sulfate (HS) (Herold et al., 1991; Shukla & Spear, 2001) . Attachment to HS is followed by interaction of gD with its receptor (Krummenacher et al., 1999 (Krummenacher et al., , 2000 . Thereafter, a concerted action involving gD, its receptor, three additional HSV glycoproteins (gB, gH and gL) and possibly an additional gH co-receptor triggers fusion of the viral envelope with a host-cell membrane (Gianni et al., 2006; Parry et al., 2005; Perez-Romero et al., 2005; Scanlan et al., 2003) . Subsequently, viral capsids and tegument proteins are released into the cytoplasm of the host cell. form of HS: 3-O-sulfated heparan sulfate (3-OS HS) (Campadelli-Fiume et al., 2000; O'Donnell et al., 2006; Shukla et al., 1999a; Tiwari et al., 2004 Tiwari et al., , 2005a Xia et al., 2002) . Each type of receptor may have a different role in HSV infection and spread in human tissues. For example, nectin-1 is expressed widely in neuronal cells and tissues (Shukla et al., 2000; Simpson et al., 2005) , whilst HVEM is expressed in lymphoid cells and the trabecular meshwork (Tiwari et al., 2005b) . Recently, we demonstrated that 3-OS HS generated by 3-O-sulfotransferase 3 is a major entry receptor for HSV-1 in corneal fibroblasts (CFs) .
In an attempt to develop an in vitro model to study HSV-2 entry into the stromal region of the eye, we used primary cultures of human CFs. The CFs were cultured from human tissues derived from healthy eye donors (14 years; provided by the Illinois Eye Bank, Chicago, IL, USA) as described previously (Clement et al., 2006; Yue & Baum, 1981) . Briefly, the CFs were grown in minimum essential medium (Invitrogen) supplemented with 10 % fetal bovine serum and 5 % calf serum (CS). To determine HSV-2 entry, cultured CFs, along with B78H1 melanoma cells, were plated in 96-well plates (2610 4 cells per well) at least 16 h prior to infection. The latter cells are resistant to HSV entry (Shukla et al., 1999b) . A recombinant strain of reporter virus, HSV-2 (333) gJ 2 , engineered to contain a cytomegalovirus-lacZ cassette in place of part of the glycoprotein J gene, was used (Martinez & Spear, 2002) . The virus expresses b-galactosidase upon entry into cells. Propagation and titration of HSV-2 (333) gJ 2 were determined on Vero cells. After 6 h, the cells were washed, permeabilized and incubated with ImmunoPure ONPG (3 mg ml
21
; Pierce) substrate for quantification of b-galactosidase activity from the input viral genome. Enzymic activity was measured by a 96-well plate reader (Spectra Max 190; Molecular Devices) " as indicated. After 6 h, the cells were washed, permeabilized and incubated with ONPG (3.0 mg ml "1 ) substrate for quantification of b-galactosidase activity from the input viral genome. The enzymic activity was measured by spectrophotometry as A 410 . Each value shown is the mean (±SD) of three or more determinations. (b) X-Gal staining of HSV-2 entry into CFs. CFs grown in Petri dishes were challenged with bgalactosidase-encoding recombinant HSV-2 (333) gJ " at 5 p.f.u. per cell. After 6 h infection at 37 6C, cells were washed with PBS, fixed, permeabilized and incubated with X-Gal (1.0 mg ml "1 ), which yields an insoluble blue product upon hydrolysis by bgalactosidase. Blue cells (representing virus entry) can be seen as dark cells. Microscopy was performed by using a ¾20 objective of a Zeiss Axiovert 100. SLIDEBOOK software, version 3.0, was used for images. (c-e) HSV-2 infection of CFs results in plaque formation. Confluent monolayers of CFs (c) were infected with HSV-2 (333) gJ " at 0.01 p.f.u. per cell for 120 min at 37 6C. Nectin-1-expressing CHO-K1 cells (d) and B78H1 melanoma cells (e) were also infected in parallel as positive and negative controls, respectively. After 48 h, the cells were fixed by using fixative buffer (2.0 % formaldehyde and 0.2 % gluteraldehyde) at room temperature for 20 min, followed by Giemsa staining for 45 min. The cells were again washed five times in PBS. Images were taken as described above by using a Zeiss Axiovert 100 microscope.
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as A 410 . Viral entry into cultured CFs was compared with that into B78H1 cells that have previously been reported to be naturally resistant to HSV-2 entry (Shukla et al., 1999b) . As shown in Fig. 1(a) , HSV-2 was able to enter CFs, but not B78H1 cells. This was further confirmed by using X-Gal (1.0 mg ml
21
; Invitrogen) staining. Cultured CFs exposed to b-galactosidase-encoding recombinants (5 p.f.u. per cell) of HSV-2 virions turned blue (Fig. 1b) . These results demonstrate that cultured CFs are susceptible to HSV-2 entry.
We next determined whether HSV-2 was able to replicate in CFs by using plaque assays. Confluent monolayers of CFs were infected with HSV-2 at 0.01 p.f.u. per cell for 120 min at 37 u C. CHO-K1 cells expressing the nectin-1 receptor and B78H1 cells were also infected under similar conditions, as positive and negative controls, respectively. About 48 h later, plaques were fixed and stained. Images were taken by using a 620 objective of an inverted microscope (Axiovert 100M; Zeiss). As indicated in Fig. 1(c) , plaques were seen with the CFs and the nectin-1-expressing CHO-K1 cells, whereas no plaques were detected in B78H1 cells. Overall, the plaques were very similar in size and number in CFs and nectin-1-expressing CHO-K1 cells (data not shown).
In order to determine whether gD receptors played an important role in HSV-2 entry into cultured CFs, we performed a gD-mediated interference assay. This assay is based on the principle that cells which are normally susceptible to virus entry become resistant upon cellular expression of gD by sequestration of the receptors by cellular gD (Shukla et al., 1999a) . Cultured human CFs were transfected with a plasmid encoding HSV-2 gD (Muggeridge, 2000) . CFs transfected with vector alone (pcDNA3.1) were used as a control. The primary CF cultures were transfected with TransIT-TKO reagent (Mirus Corporation) according to the manufacturer's instructions. Transfection efficiency in CFs was tested with a green fluorescent protein (GFP) expression plasmid. We estimated that over 80 % of cultured CFs expressed GFP as a result of transfection. The transfection efficiency was estimated by using fluorescence microscopy (see Supplementary Fig. S1 , available in JGV Online), which was very similar to a previously reported observation . Fourteen hours later, the cells were replated on 96-well plates and exposed to b-galactosidase-encoding HSV-2 (333) gJ 2 . Six hours after inoculation, cells were lysed and b-galactosidase activity was determined as a measure of virus entry. It was found that the gD-expressing CFs showed lower entry than identical cells transfected with an empty vector (Fig. 2a) . A very significant decrease in virus entry was probably due to the strong transfection efficiency seen with CFs . Therefore, HSV-2 entry into human CFs is probably mediated by gD receptors expressed on the CFs.
It has been shown previously by RT-PCR that cultured CFs express gD receptors 3-OS HS and HVEM, but not nectin-1 . As 3-OS HS is not a receptor for HSV-2, we mainly focused on HVEM as the potential receptor for HSV-2 entry into CFs. To verify the presence of HVEM on the cell surface of cultured CFs, flow cytometry was performed by using a FACSCalibur system (BD Biosciences). Wild-type CHO-K1 cells, which do not express any gD receptors (Shukla et al., 1999a) , were used as a negative control. CFs stained with fluorescein isothiocyanate (FITC)-conjugated anti-IgG secondary antibody alone were the background control. As shown in Fig. 2(b) , both HVEM-expressing CHO-K1 cells and CFs were positive for HVEM expression. Next, to verify the role of HVEM in entry, we used a previously characterized entryblocking anti-HVEM antibody (Montgomery et al., 1996; Tiwari et al., 2005b) . For the experiment, CFs plated on 96-well plates were incubated with twofold serial dilutions of the anti-HVEM antibody and a control antibody (aTGFbR II) for 90 min, starting at 1 : 20 dilutions in PBS at room temperature. Cells were then challenged with identical doses of HSV-2 (333) gJ 2 (5610 5 p.f.u. per well) prepared in PBS, 1.0 % glucose and 0.1 % heat-inactivated CS at 37 u C. After 150 min, the cells were washed once with PBS and treated for 1 min with 0.1 M citrate buffer (pH 3.0). After further washing, cells were incubated for 4 h in PBS buffer at 37 u C. The substrate, ImmunoPure ONPG (3 mg ml 21 ; Pierce), was prepared in PBS buffer (Invitrogen) with non-ionic detergent (120 ml 1 % Igepal CA-630; Sigma) and b-galactosidase activity was read as A 410 . The anti-HVEM antibody dose-response curve, compared with that generated by using control antibody a-TGFbR II, indicated that higher concentrations of anti-HVEM antibody blocked approximately 90 % of HSV-2 entry (Fig. 3) . This effect of antibody on entry blocking was very similar to what we reported recently with trabecular meshwork cells (Tiwari et al., 2005b) . It has previously been demonstrated that the anti-HVEM antibody specifically blocks the entry-mediating activity of HVEM (Montgomery et al., 1996) . Therefore, the effect of anti-HVEM antibody probably indicates a role of HVEM as the major mediator of HSV-2 entry into CFs. It is possible, although unlikely, that the antibody can produce steric interference with some other, as-yet-unknown receptor.
In summary, the demonstration of the ability of HVEM to mediate HSV-2 entry into primary cultures of CFs provides novel information on its physiological relevance as a receptor for HSV-2. Although many reports have indicated its significance in HSV-1 entry (Montgomery et al., 1996; Tiwari et al., 2005b) , ours is the first of its kind to demonstrate the importance of HVEM for HSV-2 infection. Our study is also unique because it demonstrates, for the first time, that the two serotypes of HSV prefer separate receptors for entering CFs. HSV-1 prefers 3-OS HS , whereas HSV-2 exploits HVEM. The use of HVEM, which is a member of the tumour necrosis factor receptor family, by HSV-2 might also have implications for the unusual immune response that is observed during HSK. HVEM is a regulator of the immune response mediated by T cells and antigen-presenting cells (Murphy et al., 2006) . It is tempting to speculate that HSV-2 gD can modulate the normal activity of HVEM either by competing with its normal physiological ligands (Murphy et al., 2006) or by altering its normal expression, or both. Any such change can have profound immune consequences -a possibility that needs to be examined in the light of our discovery that HVEM is expressed by the cells of the corneal stroma and is used by HSV-2 for entry. Fig. 3 . Anti-HVEM antibody inhibits HSV-2 entry into cultured human CFs. CFs plated in 96-well plates were pre-incubated at room temperature with twofold dilutions of anti-HVEM antibody (Ab) and a control Ab (a-TGFbR II) for 90 min. Cells were then challenged at 37 6C with equal doses of HSV-2 (333) gJ " at 5¾10 5 p.f.u. per well. After 150 min, cells were washed and treated for 1 min with 0.1 M citrate buffer (pH 3.0). After further washing, cells were incubated at 37 6C for 4 h in PBS. The substrate, ImmunoPure ONPG, was prepared in PBS buffer with non-ionic detergent (120 ml 1 % Igepal CA-630; Sigma) and b-galactosidase activity was read as A 410 . The experiment was repeated three times with similar results.
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